Recursion Pharmaceuticals, Inc. (RXRX)
Largest Insider Buys in Sector
RXRX Stock Price History Chart
RXRX Stock Performance
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 …
Insider Activity of Recursion Pharmaceuticals, Inc.
Over the last 12 months, insiders at Recursion Pharmaceuticals, Inc. have bought $0 and sold $15.73M worth of Recursion Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Recursion Pharmaceuticals, Inc. have bought $66.24M and sold $15.86M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 66,822 shares for transaction amount of $522,354 was made by Mubadala Investment Co PJSC (10 percent owner) on 2023‑03‑02.
List of Insider Buy and Sell Transactions, Recursion Pharmaceuticals, Inc.
| 2024-11-14 | Sale | Chief Executive Officer | 20,000 0.0076% | $7.35 | $147,000 | -15.99% | ||
| 2024-11-13 | Sale | Chief Financial Officer | 15,000 0.0055% | $7.66 | $114,876 | -17.49% | ||
| 2024-11-13 | Sale | Chief Executive Officer | 20,000 0.0075% | $7.74 | $154,800 | -17.49% | ||
| 2024-11-12 | Sale | director | 11,447 0.0042% | $7.64 | $87,457 | -19.39% | ||
| 2024-11-12 | Sale | Chief Financial Officer | 15,000 0.0055% | $7.64 | $114,629 | -19.39% | ||
| 2024-10-29 | Sale | director | 11,447 0.004% | $6.72 | $76,926 | -0.89% | ||
| 2024-10-24 | Sale | President and COO | 6,000 0.002% | $6.31 | $37,855 | 0.00% | ||
| 2024-10-15 | Sale | director | 11,447 0.0038% | $6.67 | $76,326 | +1.20% | ||
| 2024-10-09 | Sale | Chief Financial Officer | 15,000 0.0047% | $6.36 | $95,375 | +8.94% | ||
| 2024-10-08 | Sale | Chief Financial Officer | 15,000 0.0047% | $6.32 | $94,757 | +3.73% | ||
| 2024-10-03 | Sale | Chief Executive Officer | 20,000 0.006% | $6.08 | $121,600 | +9.82% | ||
| 2024-10-02 | Sale | Chief Executive Officer | 20,000 0.0061% | $6.16 | $123,200 | +8.67% | ||
| 2024-10-01 | Sale | director | 11,447 0.0035% | $6.22 | $71,150 | +7.46% | ||
| 2024-09-26 | Sale | President and COO | 6,000 0.0022% | $7.00 | $42,005 | -2.79% | ||
| 2024-09-17 | Sale | director | 11,447 0.0042% | $6.84 | $78,333 | -1.33% | ||
| 2024-09-11 | Sale | Chief Financial Officer | 15,000 0.0054% | $6.32 | $94,730 | +2.92% | ||
| 2024-09-10 | Sale | Chief Financial Officer | 15,000 0.0053% | $6.17 | $92,499 | +5.22% | ||
| 2024-09-05 | Sale | Chief Executive Officer | 20,000 0.0072% | $6.14 | $122,800 | +7.46% | ||
| 2024-09-04 | Sale | Chief Executive Officer | 20,000 0.0072% | $6.04 | $120,800 | +8.52% | ||
| 2024-09-03 | Sale | director | 11,447 0.0043% | $6.27 | $71,718 | +8.81% |
Insider Historical Profitability
| Mubadala Investment Co PJSC | 10 percent owner | 12985927 4.6444% | $5.71 | 42 | 0 | +0.28% |
| Lux Ventures IV, L.P. | 10 percent owner | 100000 0.0358% | $5.71 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| ARK Investment Management LLC | $245.14M | 9.01 | 24.59M | +19.04% | +$39.21M | 0.85 | |
| Baillie Gifford Co | $239.96M | 8.82 | 24.07M | -0.46% | -$1.11M | 0.19 | |
| The Vanguard Group | $159.67M | 5.87 | 16.01M | +2.23% | +$3.49M | <0.01 | |
| BlackRock | $122.84M | 4.51 | 12.32M | -0.59% | -$726,184.90 | <0.01 | |
| Kinnevik Ab Publ | $103.74M | 3.81 | 10.41M | 0% | +$0 | 100 |